Our finding that DAT1 10/10 carriers had abnormal reward outcome related activity in the orbitofrontal cortex could reflect an increased vulnerability for PD-related dopaminergic cell loss in this region. This evidence concerns the gene SLC6A3 and Parkinson disease.